Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.000
-0.010 (-0.99%)
Aug 27, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 27 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year.
Employees
27
Change
n/a
Growth
n/a
Revenue / Employee
$1,299,630
Profits / Employee
$418,815
Market Cap
31.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 27 | 0 | - |
| Mar 31, 2026 | 25 | -6 | -19.35% |
| Dec 31, 2025 | 25 | -12 | -32.43% |
| Sep 30, 2025 | 25 | -12 | -32.43% |
| Jun 30, 2025 | 27 | -10 | -27.03% |
| Mar 31, 2025 | 31 | -18 | -36.73% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Sep 30, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| BeyondSpring | 44 |
| Quince Therapeutics | 38 |
| Kyntra Bio | 34 |
| BriaCell Therapeutics | 16 |
| Barinthus Biotherapeutics | 14 |
| NanoViricides | 7 |
| Lite Strategy | 4 |
ATNM News
- 13 days ago - Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PRNewsWire
- 20 days ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 20 days ago - Actinium Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 3 months ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 3 months ago - Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026 - TheFly
- 3 months ago - Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PRNewsWire
- 3 months ago - Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PRNewsWire
- 3 months ago - Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer - TheFly